دوره 6، شماره 3 - ( 9-1401 )
جلد 6 شماره 3 صفحات 16-10 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bagadi V H C, Gelli V S L, Muram Reddy V L, Badugu K M. Clinico-Immunohistochemical Analysis of Ovarian Tumors in a South Indian Population: A Single-Center Study. jcbr 2022; 6 (3) :10-16
URL: http://jcbr.goums.ac.ir/article-1-369-fa.html
URL: http://jcbr.goums.ac.ir/article-1-369-fa.html
Clinico-Immunohistochemical Analysis of Ovarian Tumors in a South Indian Population: A Single-Center Study. Journal of Clinical and Basic Research. 1401; 6 (3) :10-16
چکیده: (1707 مشاهده)
Background and objectives: In India, ovarian tumors are the fifth leading cause of death in women. They account for 6% of all cancers in women. The present study aimed to provide support for a new theory of ovarian carcinogenesis by investigating the frequency of ovarian tumors and determining whether the Ki-67 labeling index and p53 overexpression help in differentiating borderline and malignant surface epithelial tumors.
Methods: The study included all ovarian tumor specimens sent for histopathological examination to the Department of Pathology of Narayana Medical College between June 2017 and October 2019.
Results: The frequency of benign epithelial and malignant tumors was 85.47% and 11.97%, respectively. Surface epithelial tumors (81.96%) and germ cell tumors (8.54%) were the most common ovarian tumors. In immunohistochemistry, p53 overexpression in surface epithelial neoplasms showed moderate positivity in all 2 cases of serous carcinomas, while 2 out of 6 mucinous carcinomas cases showed weak positivity. All six cases of mucinous carcinomas showed a Ki-67 labeling index of 26-50%. Serous carcinomas showed a high index of 51%, while mucinous carcinomas had a mean index of 37%. Overexpression of Ki-67 was significantly more common in malignant surface epithelial neoplasms (41.83%) when compared with borderline epithelial neoplasms (27%) (p<0.001).
Conclusion: In comparison to borderline serous and mucinous tumors, Ki-67 overexpression is significantly higher common in malignant surface epithelial tumors. Moreover, p53 overexpression is significantly more common in serous carcinoma when compared with borderline serous tumors but not mucinous tumors. Overall, these markers could be beneficial for diagnosing difficult cases and predicting prognosis.
Methods: The study included all ovarian tumor specimens sent for histopathological examination to the Department of Pathology of Narayana Medical College between June 2017 and October 2019.
Results: The frequency of benign epithelial and malignant tumors was 85.47% and 11.97%, respectively. Surface epithelial tumors (81.96%) and germ cell tumors (8.54%) were the most common ovarian tumors. In immunohistochemistry, p53 overexpression in surface epithelial neoplasms showed moderate positivity in all 2 cases of serous carcinomas, while 2 out of 6 mucinous carcinomas cases showed weak positivity. All six cases of mucinous carcinomas showed a Ki-67 labeling index of 26-50%. Serous carcinomas showed a high index of 51%, while mucinous carcinomas had a mean index of 37%. Overexpression of Ki-67 was significantly more common in malignant surface epithelial neoplasms (41.83%) when compared with borderline epithelial neoplasms (27%) (p<0.001).
Conclusion: In comparison to borderline serous and mucinous tumors, Ki-67 overexpression is significantly higher common in malignant surface epithelial tumors. Moreover, p53 overexpression is significantly more common in serous carcinoma when compared with borderline serous tumors but not mucinous tumors. Overall, these markers could be beneficial for diagnosing difficult cases and predicting prognosis.
نوع مقاله: پژوهشي |
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).